Uncoupling of cell growth and proliferation results in enhancement of productivity in p21CIP1‐arrested CHO cells
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Chinese hamster ovary cells have been engineered to inducibly over‐express the p21 CIP1 cyclin‐dependent kinase inhibitor, to achieve cell cycle arrest and increase cell productivity. In p21 CIP1‐arrested cells production of antibody from a stably integrated lgG4 gene, was enhanced approximately fourfold. The underlying physiological basis for enhanced productivity was investigated by measuring a range of cellular and metabolic parameters. Interestingly, the average cell volume of arrested cells was approximately fourfold greater than that of proliferating cells. This was accompanied by significant increases in mitochondrial mass, mitochondrial activity, and ribosomal protein S6 levels. Our results suggest that p21 CIP1‐induced cell cycle arrest uncouples cell growth from cell‐cycle progression, and provides new insight into how improved productivity can be achieved in a cell line commonly used for large‐scale production of pharmaceutical proteins. © 2004 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Relationship between cell size, cell cycle and specific recombinant protein productivity
Lloyd, D. R., Holmes, P., Jackson, L. P., Emery, A. N., & Al-Rubeai, M. (2000) · Cytotechnology · doi:10.1023/a:1008103730027 · Cited by 93 · cited 1×
“G1-phase of the cell cycle of some cell lines may be a privileged position for increased production of heterologous proteins (Al-Rubeai and Emory, 1990; Al-Rubeai et al., 1991, 1992; Kaufman et al., 2001; Lloyd et al., 2000; Suzuki and Ollis, 1990).”
BackgroundSelf-citation
Cited by
Kim, J. Y., Kim, Y.-G., & Lee, G. M. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3758-5 · Cited by 801
Cell culture processes for monoclonal antibody production
Li, F., Vijayasankaran, N., Shen, A. (., Kiss, R., & Amanullah, A. (2010) · mAbs · doi:10.4161/mabs.2.5.12720 · Cited by 739
Expression systems for therapeutic glycoprotein production
Durocher, Y., & Butler, M. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.008 · Cited by 386
The art of CHO cell engineering: A comprehensive retrospect and future perspectives
Fischer, S., Handrick, R., & Otte, K. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.10.015 · Cited by 312
Guidelines to cell engineering for monoclonal antibody production
Rita Costa, A., Elisa Rodrigues, M., Henriques, M., Azeredo, J., & Oliveira, R. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.10.002 · Cited by 178
“Attempts made in this sense include modulation of c-jun [154], growing under glutamine limitation [131], inducible expression of p27 [70,136] and p21cip1 [137,155], and use of rapamycin [152,156].”
BackgroundSunley, K., & Butler, M. (2010) · Biotechnology Advances · doi:10.1016/j.biotechadv.2010.02.003 · Cited by 136
“It has been observed that cells at the end of G1 are typically more metabolically active, larger in size (Bi et al., 2004, Carvalhal et al., 2003), and actively express many genes responsible for ribosome biosynthesis (Dez and Tollervey, 2004).”
BackgroundInfluentialDu, Z., Treiber, D., McCarter, J. D., Fomina‐Yadlin, D., Saleem, R. A., McCoy, R. E., Zhang, Y., Tharmalingam, T., Leith, M., Follstad, B. D., et al. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25332 · Cited by 113
Ghorbaniaghdam, A., Chen, J., Henry, O., & Jolicoeur, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090832 · Cited by 71
“Moreover, media composition and culture conditions, as well as their management along with culture duration, have to be optimized to achieve not only the objective of desired cell productivity and viability but also mAbs quality specifications [5].”
BackgroundSelection of chemically defined media for CHO cell fed-batch culture processes
Pan, X., Streefland, M., Dalm, C., Wijffels, R. H., & Martens, D. E. (2017) · Cytotechnology · doi:10.1007/s10616-016-0036-5 · Cited by 70
Ha, T. K., Hansen, A. H., Kol, S., Kildegaard, H. F., & Lee, G. M. (2018) · Biotechnology Journal · doi:10.1002/biot.201700425 · Cited by 40
Detailed understanding of enhanced specific antibody productivity in NS0 myeloma cells
Khoo, S. H. G., & Al‐Rubeai, M. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22041 · Cited by 38
“Had a clone with lower specific productivity been used, like one of those shown by Bi et al. (2004), the overall yield could have been different.”
BackgroundMethodResultInfluentialSelf-citationTranscriptome Analysis of CHO Cell Size Increase During a Fed-Batch Process
Pan, X., Alsayyari, A. A., Dalm, C., Hageman, J. A., Wijffels, R. H., & Martens, D. E. (2019) · Biotechnology Journal · doi:10.1002/biot.201800156 · Cited by 22
Metadata
- Authors
- Bi, J., Shuttleworth, J., & Al‐Rubeai, M.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2004-02-04
- Volume
- 85
- Issue
- 7
- Pages
- 741-749
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2131740110
- Cited by
- 128
- References
- 2
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.